Coherus Oncology, Inc.

CHRS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$29-$238-$292-$287
Dep. & Amort.$5$4$4$3
Deferred Tax$0$0$0$9
Stock-Based Comp.$28$0$51$51
Change in WC$56-$37-$79$42
Other Non-Cash-$138$96$75$143
Operating Cash Flow-$20-$175-$241-$37
Investing Activities
PP&E Inv.$0-$0-$2-$1
Net Acquisitions$0$1$0$1
Inv. Purchases$0-$20-$127-$182
Inv. Sales/Matur.$15$158$0$181
Other Inv. Act.$215$6-$37-$137
Investing Cash Flow$230$145-$167-$138
Financing Activities
Debt Repay.-$223$0$50-$1
Stock Issued$1$74$6$41
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$35-$5-$2$12
Financing Cash Flow-$187$70$54$52
Forex Effect$0-$0$0$0
Net Chg. in Cash$23$39-$354-$124
Supplemental Information
Beg. Cash$103$64$418$542
End Cash$126$103$64$418
Free Cash Flow-$20-$175-$243-$39
Coherus Oncology, Inc. (CHRS) Financial Statements & Key Stats | AlphaPilot